Evidence map›Paper›PMID 41675395›Full record

ArticleJHLT open2026

Heart-Lung transplantation: Meeting allocation challenges in France.

Justin Issard, Claire Merveilleux du Vignaux, Sébastien Renard, Thierry Lepoivre, Paul Michel Mertes, Richard Dorent, Eric Epailly, Sébastien Hascoet, Anne Olland, Jérôme Le Pavec and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Justin IssardInserm UMR_S 999 "Hypertension Artérielle Pulmonaire Physiopathologie et Innovation thérapeutique", Université Paris-Saclay, Le Plessis-Robinson, France.
Claire Merveilleux du VignauxDepartment of Respiratory Medicine, National Coordinating Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, and Claude Bernard University Lyon 1, France.
Sébastien RenardDepartment of Cardiology, Pulmonary Hypertension Competence Regional, Hôpital La Timone, Marseille, France.
Thierry LepoivreDepartment of Anesthesia and Critical Care, Nantes Université, CHU Nantes, Nantes, France.
Paul Michel MertesDepartment of Anesthesia and Critical Care, University Hospital of Strasbourg, Strasbourg, France.
Richard DorentAgence de la Biomédecine, Saint Denis, France.
Eric EpaillyDepartment of Cardiovascular Surgery, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Sébastien HascoetDepartment of Congenital Heart Diseases, Centre de Référence Malformations Cardiaques Congénitales Complexes M3C, Hôpital Marie Lannelongue, Groupe, Université Paris-Saclay, Le Plessis Robinson, France.
Anne OllandInserm UMR 1260 "Regenerative Nanomedicine", University of Strasbourg, France.
Jérôme Le PavecDepartment of Pneumology and Lung Transplant, Hôpital Marie-Lannelongue, Inserm UMR_S 999 "Hypertension Artérielle Pulmonaire Physiopathologie et Innovation thérapeutique", Université Paris-Saclay, Le Plessis-Robinson, France.
Elie FadelInserm UMR_S 999 "Hypertension Artérielle Pulmonaire Physiopathologie et Innovation thérapeutique", Université Paris-Saclay, Le Plessis-Robinson, France.
Laurent SavaleDepartment of Respiratory and Intensive Care Medicine, Assistance Publique-Hôpitaux de Paris (AP-HP), ERN-LUNG, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Inserm UMR_S 999 "Hypertension Artérielle Pulmonaire Physiopathologie et Innovation thérapeutique", Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Olaf MercierInserm UMR_S 999 "Hypertension Artérielle Pulmonaire Physiopathologie et Innovation thérapeutique", Université Paris-Saclay, Le Plessis-Robinson, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Our study aims to describe the French heart-lung graft allocation system, to compare it with allocation systems used in other countries, and to explore potential solutions to improve access to this rare transplantation procedure. Methods: Our study integrates published literature and multidisciplinary expert opinions to examine heart-lung graft allocation in France. Results: The heart-lung transplantation (HLTx) programme was initiated in France in 1987. The number of procedures then increased steadily until the 2010s. Improved knowledge on right ventricular function recovery after double lung transplantation (LTx) for pulmonary hypertension combined with the organ shortage then led to a sharp drop in the number of HLTx recipients worldwide. In France, the number of HLTx procedures is only about ten per year and the main indication is Eisenmenger syndrome. Most HLTx candidates in France receive grafts only if they are in the high-urgency category highlighting the difficulty of access to heart-lung transplants. A re-appraisal of graft allocation rules thus seems mandatory to allow graft access to patients who do not meet high-urgency criteria and whose better general health predicts better post-HLTx outcomes. Conclusions: As HLTx candidates in France are placed on the heart-transplant list in competition with heart-only transplant candidate, one option would be to reconsider the heart score assigned to HLTx candidates upon listing.

Indexed as

Eisenmenger syndromeHeart–lung transplantationOrgan allocationPulmonary arterial hypertensionPulmonary hypertension

Identifiers

PMID41675395
PMCPMC12887774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.